In vitro assessment of metabolic drugdrug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P450 enzyme identification, inhibition, and induction studies

Xenobiotica

Volumn 40, Issue 11, 2010, Pages 721-729

  Li, Yan ^a   Zhou, Diansong ^a   Ferguson, Stephen S ^b   Dorff, Peter ^a   Simpson, Thomas R ^a   Grimm, Scott W ^a  

^a ASTRAZENECA   (United Kingdom)

^b Invitrogen Corporation/CellzDirect   (United States)

Author keywords

AZD2624; CYP enzyme identification; CYP induction; CYP inhibition; Enzyme kinetics

Indexed keywords

AZD 2624; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; KETONE; MIDAZOLAM; NEUROKININ 3 RECEPTOR ANTAGONIST; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROXYLATION; IC 50; IN VITRO STUDY; LIVER MICROSOME METABOLISM; PHARMACODYNAMICS;

AMINOQUINOLINES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ENZYME INDUCTION; HUMANS; MICROSOMES, LIVER; RECEPTORS, NEUROKININ-3; SCHIZOPHRENIA; SULFONAMIDES;

EID: 77957962489     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2010.512670     Document Type: Article

References (25)

1. Almeida TA, Rojo J, Nieto PM, Pinto FM, Hernandez M, Martín JD, Candenas ML. (2004). Tachykinins and tachykinin recep-tors: structure and activity relationships. Curr Med Chem 11:2045-2081.
2. Chen Y, Ferguson SS, Negishi M, Goldstein JA. (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ter 308, 495-501.
3. Dawson LA, Smith PW. (2010). Terapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr Pharm Des 16:344-357.
4. Denison MS, Nagy SR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43:309-334.
5. Evangelista S. (2005). Talnetant GlaxoSmithKline. Curr Opin Investig Drugs 6:717-721.
6. Gerard NP, Bao L, Xiao-Ping H, Gerard C. (1993). Molecular aspects of the tachykinin receptors. Regul Pept 43:21-35.
7. Gibson GG, Plant NJ, Swales KE, Ayrton A, El-Sankary W. (2002). Receptor-dependent transcriptional activation of cytochrome P4503A genes: induction mechanisms, species diferences and interindividual variation in man. Xenobiotica 32:165-206.
8. Guengerich FP. (1999). Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
9. Hewitt NJ, Lecluyse EL, Ferguson SS. (2007). Induction of hepatic cytochrome P450 enzymes: methods, mechanisms, recom-mendations, and in vitro-in vivo correlations. Xenobiotica 37:1196-1224.
10. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Tummel K, Boguski MS, Schuetz E. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-391.
11. Langlois X, Wintmolders C, te Riele P, Leysen JE, Jurzak M. (2001). Detailed distribution of Neurokinin 3 receptors in the rat, guinea pig and gerbil brain: a comparative autoradiographic study. Neuropharmacology 40:242-253.
12. LeCluyse EL. (2001). Human hepatocyte culture systems for the in vitro evaluation of cytochrome P450 expression and regulation. Eur J Pharm Sci 13:343-368.
13. Li XQ, Andersson TB, Ahlström M, Weidolf L. (2004). Comparison of inhibitory efects of the proton pump-inhibiting drugs omepra-zole, esomeprazole, lansoprazole, pantoprazole, and rabepra-zole on human cytochrome P450 activities. Drug Metab Dispos 32:821-827.
14. Maggi CA. (1995). Te mammalian tachykinin receptors. Gen Pharmacol 26:911-944.
15. Meltzer HY, Arvanitis L, Bauer D, Rein W; Meta-Trial Study Group. (2004). Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoafective disorder. Am J Psychiatry 161:975-984.
16. Nakanishi S. (1991). Mammalian tachykinin receptors. Annu Rev Neurosci 14:123-136.
17. Simpson TR, Kang J, Albert JS, Alhambra C, Koether GM, Woods JM, Li Y. (2007). Preparation of quinoline derivatives as neurokinin-3 receptor antagonists. PCT Int Appl 48pp WO2007069977.
18. Simpson TR, Gadient R, Li Y, Kanes S, Lengel D, Potts W, Yang W, Kang J, Woods JM, Alhambra C, Albert JS, Koether GM, Do ML, Scott C, Sobotka-Briner C, Maier D, Medd A, Mrzljak L, Defay T, Furlong S, Mathisen D, Sygowski L, Williams A, Condon S, Wilkins D, Bi V, Morelli J, Otieno M, Kelsall J, Smith M, Stong D, Desai D, Tollemar U, Keith R, Boss A, Davis P, Sloan A, Zhou D, Pierson E, Cantagallo K, Litman R, Gertsik LG, Dragan Y, Simpson B, Eisman M, Xiao A, Litwin LC, Sweitzer DE, Wang Y, Ennis DJ, Garber S, Rak IW. (2010). Discovery of AZD2624: A potent and selective NK3 antagonist to test the NK3 hypothesis in schizo-phrenia. 239th ACS National Meeting, San Francisco, CA, United States, March 21-25, MEDI-35.
19. Spooren W, Riemer C, Meltzer H. (2005). Opinion: NK3 receptor antagonists: the next generation of antipsychotics? Nat Rev Drug Discov 4:967-975.
20. US Food and Drug Administration. Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis and Implications for Dosing and Labeling, 2006. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf. Accessed March 28, 2010.
21. Wang H, Faucette S, Moore R, Sueyoshi T, Negishi M, LeCluyse E. (2004). Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J Biol Chem 279:29295-29301.
22. Wang YH, Jones DR, Hall SD. (2005). Diferential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos 33:664-671.
23. Wang B, Wang J, Huang SQ, Su HH, Zhou SF. (2009). Genetic polymor-phism of the human cytochrome P450 2C9 gene and its clinical signifcance. Curr Drug Metab 10:781-834.
24. Westlind-Johnsson A, Malmebo S, Johansson A, Otter C, Andersson TB, Johansson I, Edwards RJ, Boobis AR, Ingelman-Sundberg M. (2003). Comparative analysis of CYP3A expression in human liver suggests only a minor role for CYP3A5 in drug metabolism. Drug Metab Dispos 31:755-761.
25. Wu LH, Vartanian MA, Oxender DL, Chung FZ. (1994). Identifcation of methionine134 and alanine146 in the second transmembrane segment of the human tachykinin NK3 receptor as reduces involved in species-selective binding to SR 48968. Biochem Biophys Res Commun 198:961-966.